Literature DB >> 30708038

A critical review of the role of M2PYK in the Warburg effect.

Robert A Harris1, Aron W Fenton2.   

Abstract

It is becoming generally accepted in recent literature that the Warburg effect in cancer depends on inhibition of M2PYK, the pyruvate kinase isozyme most commonly expressed in tumors. We remain skeptical. There continues to be a general lack of solid experimental evidence for the underlying idea that a bottle neck in aerobic glycolysis at the level of M2PYK results in an expanded pool of glycolytic intermediates (which are thought to serve as building blocks necessary for proliferation and growth of cancer cells). If a bottle neck at M2PYK exists, then the remarkable increase in lactate production by cancer cells is a paradox, particularly since a high percentage of the carbons of lactate originate from glucose. The finding that pyruvate kinase activity is invariantly increased rather than decreased in cancer undermines the logic of the M2PYK bottle neck, but is consistent with high lactate production. The "inactive" state of M2PYK in cancer is often described as a dimer (with reduced substrate affinity) that has dissociated from an active tetramer of M2PYK. Although M2PYK clearly dissociates easier than other isozymes of pyruvate kinase, it is not clear that dissociation of the tetramer occurs in vivo when ligands are present that promote tetramer formation. Furthermore, it is also not clear whether the dissociated dimer retains any activity at all. A number of non-canonical functions for M2PYK have been proposed, all of which can be challenged by the finding that not all cancer cell types are dependent on M2PYK expression. Additional in-depth studies of the Warburg effect and specifically of the possible regulatory role of M2PYK in the Warburg effect are needed.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30708038      PMCID: PMC6525063          DOI: 10.1016/j.bbcan.2019.01.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  255 in total

Review 1.  Dysregulated pH: a perfect storm for cancer progression.

Authors:  Bradley A Webb; Michael Chimenti; Matthew P Jacobson; Diane L Barber
Journal:  Nat Rev Cancer       Date:  2011-08-11       Impact factor: 60.716

2.  The M2-type isoenzyme of pyruvate kinase phosphorylates prothymosin α in proliferating lymphocytes.

Authors:  Cristina Díaz-Jullien; David Moreira; Concepción Sofía Sarandeses; Guillermo Covelo; Pablo Barbeito; Manuel Freire
Journal:  Biochim Biophys Acta       Date:  2010-10-23

3.  Conversion of non-allosteric pyruvate kinase isozyme into an allosteric enzyme by a single amino acid substitution.

Authors:  Y Ikeda; T Tanaka; T Noguchi
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

4.  Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation.

Authors:  Jiangbin Ye; Anthony Mancuso; Xuemei Tong; Patrick S Ward; Jing Fan; Joshua D Rabinowitz; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-16       Impact factor: 11.205

Review 5.  Tumor markers in detection of lung cancer.

Authors:  Joachim Schneider
Journal:  Adv Clin Chem       Date:  2006       Impact factor: 5.394

6.  Identification of small molecule inhibitors of pyruvate kinase M2.

Authors:  Matthew G Vander Heiden; Heather R Christofk; Eli Schuman; Alexander O Subtelny; Hadar Sharfi; Edward E Harlow; Jun Xian; Lewis C Cantley
Journal:  Biochem Pharmacol       Date:  2009-12-11       Impact factor: 5.858

7.  TSC22D2 interacts with PKM2 and inhibits cell growth in colorectal cancer.

Authors:  Fang Liang; Qiao Li; Xiayu Li; Zheng Li; Zhaojian Gong; Hao Deng; Bo Xiang; Ming Zhou; Xiaoling Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong
Journal:  Int J Oncol       Date:  2016-07-04       Impact factor: 5.650

8.  M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth.

Authors:  Marta Cortés-Cros; Christelle Hemmerlin; Stephane Ferretti; Juan Zhang; John S Gounarides; Hong Yin; Alban Muller; Anne Haberkorn; Patrick Chene; William R Sellers; Francesco Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-24       Impact factor: 11.205

9.  Protein tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylation.

Authors:  Ahmed Bettaieb; Jesse Bakke; Naoto Nagata; Kosuke Matsuo; Yannan Xi; Siming Liu; Daniel AbouBechara; Ramzi Melhem; Kimber Stanhope; Bethany Cummings; James Graham; Andrew Bremer; Sheng Zhang; Costas A Lyssiotis; Zhong-Yin Zhang; Lewis C Cantley; Peter J Havel; Fawaz G Haj
Journal:  J Biol Chem       Date:  2013-05-02       Impact factor: 5.157

10.  Heterogeneity of glycolytic enzyme activity and isozyme composition of pyruvate kinase in breast cancer.

Authors:  A Hennipman; B A van Oirschot; J Smits; G Rijksen; G E Staal
Journal:  Tumour Biol       Date:  1988
View more
  9 in total

Review 1.  An overview of structure, function, and regulation of pyruvate kinases.

Authors:  Norbert Schormann; Katherine L Hayden; Paul Lee; Surajit Banerjee; Debasish Chattopadhyay
Journal:  Protein Sci       Date:  2019-08-12       Impact factor: 6.725

2.  Cancer-associated mutations in human pyruvate kinase M2 impair enzyme activity.

Authors:  Vivian M Liu; Andrea J Howell; Aaron M Hosios; Zhaoqi Li; William J Israelsen; Matthew G Vander Heiden
Journal:  FEBS Lett       Date:  2019-11-16       Impact factor: 4.124

3.  ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth.

Authors:  Wai Kit Ma; Dillon M Voss; Juergen Scharner; Ana S H Costa; Kuan-Ting Lin; Hyun Yong Jeon; John E Wilkinson; Michaela Jackson; Frank Rigo; C Frank Bennett; Adrian R Krainer
Journal:  Cancer Res       Date:  2022-03-01       Impact factor: 13.312

Review 4.  The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy.

Authors:  Tiejun Wang; Yan Jiao; Yuechen Zhao; Yanqing Li; Ruifeng Zhang; Feng Wang
Journal:  Onco Targets Ther       Date:  2020-06-11       Impact factor: 4.147

Review 5.  Noncoding RNAs in the Glycolysis of Ovarian Cancer.

Authors:  Chunmei Zhang; Ning Liu
Journal:  Front Pharmacol       Date:  2022-03-30       Impact factor: 5.810

6.  Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.

Authors:  Maria Apostolidi; Ioannis A Vathiotis; Viswanathan Muthusamy; Patricia Gaule; Brandon M Gassaway; David L Rimm; Jesse Rinehart
Journal:  Cancer Res       Date:  2021-06-21       Impact factor: 12.701

7.  Multi-Tissue Acceleration of the Mitochondrial Phosphoenolpyruvate Cycle Improves Whole-Body Metabolic Health.

Authors:  Abudukadier Abulizi; Rebecca L Cardone; Romana Stark; Sophie L Lewandowski; Xiaojian Zhao; Joelle Hillion; Lingjun Ma; Raghav Sehgal; Tiago C Alves; Craig Thomas; Charles Kung; Bei Wang; Stephan Siebel; Zane B Andrews; Graeme F Mason; Jesse Rinehart; Matthew J Merrins; Richard G Kibbey
Journal:  Cell Metab       Date:  2020-11-03       Impact factor: 27.287

8.  Pyruvate Kinase Controls Signal Strength in the Insulin Secretory Pathway.

Authors:  Sophie L Lewandowski; Rebecca L Cardone; Hannah R Foster; Thuong Ho; Evgeniy Potapenko; Chetan Poudel; Halena R VanDeusen; Sophia M Sdao; Tiago C Alves; Xiaojian Zhao; Megan E Capozzi; Arnaldo H de Souza; Ishrat Jahan; Craig J Thomas; Craig S Nunemaker; Dawn Belt Davis; Jonathan E Campbell; Richard G Kibbey; Matthew J Merrins
Journal:  Cell Metab       Date:  2020-11-03       Impact factor: 27.287

9.  PKM2 Modulation in Head and Neck Squamous Cell Carcinoma.

Authors:  Verena Boschert; Jonas Teusch; Urs D A Müller-Richter; Roman C Brands; Stefan Hartmann
Journal:  Int J Mol Sci       Date:  2022-01-11       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.